Literature DB >> 1642253

Testosterone deficiency as a risk factor for hip fractures in men: a case-control study.

J A Jackson1, M W Riggs, A M Spiekerman.   

Abstract

The objective of this study was to determine whether decreased gonadal function is a risk factor for hip fracture in elderly men. The study was a matched case-control study performed at an in-hospital orthopedic service at a semi-rural and academic tertiary care center. The patients were seventeen men who presented with hip fractures after simple falls over a 10-month period, 11 men with a history of hip fractures in the preceding 25 months, and 28 randomly selected age-, race-, and living status-matched control subjects (mean age 73 years). Serum pooled total testosterone (9.2 +/- 5.5 nmol/L vs. 12.8 +/- 5.4 nmol/L; p less than 0.02) and free testosterone (37.9 +/- 18.8 pmol/L vs. 48.4 +/- 20.6 pmol/L; p less than 0.03) were significantly lower in hip fracture vs. control patients. Testosterone deficiency was found in 20 (71%) hip fracture men vs. 9 (32%) of the controls (p = 0.003; odds ratio 5.3). Analysis of testosterone values within the stratum of absence of any chronic disorder revealed similar results. Serum 25-hydroxyvitamin D levels were significantly lower in the hip fracture group than in control men (p less than 0.001). The conclusion is that gonadal deficiency appears to be an important and heretofore understudied risk factor for hip fractures in men. Prevention of hip fractures in men may involve early recognition and treatment of testosterone deficiency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642253     DOI: 10.1097/00000441-199207000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  38 in total

1.  For and against: The male menopause--does it exist?

Authors:  D C Gould; R Petty; H S Jacobs
Journal:  BMJ       Date:  2000-03-25

2.  The male menopause: does it exist?: for: some men need investigation and testosterone treatment

Authors: 
Journal:  West J Med       Date:  2000-08

Review 3.  Osteoporosis in men.

Authors:  G M Prelevic
Journal:  J R Soc Med       Date:  2001-12       Impact factor: 5.344

Review 4.  Osteoporosis in men: are we ready to diagnose and treat?

Authors:  H M Perry; J E Morley
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 5.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

6.  Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors.

Authors:  Neerad C Mishra; Jules Rir-sima-ah; R Thomas Boyd; Shashi P Singh; Sravanthi Gundavarapu; Raymond J Langley; Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

7.  Bone mass and mineral metabolism in Klinefelter's syndrome.

Authors:  G Luisetto; I Mastrogiacomo; G Bonanni; G Pozzan; S Botteon; L Tizian; P Galuppo
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

Review 8.  Andropause: is the emperor wearing any clothes?

Authors:  S H Tariq; M T Haren; M J Kim; J E Morley
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

9.  Testosterone levels increase in association with recovery from acute fracture in men.

Authors:  A S Cheung; S Baqar; R Sia; R Hoermann; S Iuliano-Burns; T D T Vu; C Chiang; E J Hamilton; E Gianatti; E Seeman; J D Zajac; M Grossmann
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

10.  Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

Authors:  Joseph M Unger; Cathee Till; Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; Jason D Wright; William E Barlow; Scott D Ramsey; Lori M Minasian; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2016-08-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.